Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease

NeuroToxicology

Volumn 53, Issue , 2016, Pages 148-152

  Yeh, Yi Chun ^a,c   Huang, Mei Feng ^a,c   Liang, Shih Shin ^b   Hwang, Shang Jyh ^a,c   Tsai, Jer Chia ^a,c   Liu, Tai Ling ^a,c   Wu, Ping Hsun ^c   Yang, Yi Hsin ^b   Kuo, Kuang Che ^d   Kuo, Mei Chuan ^a,c   Chen, Cheng Sheng ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chronic kidney disease; Cognitive function; Indoxyl sulfate; P Cresyl sulfate; Uremic toxin

Indexed keywords

4 CRESYL SULFATE; INDICAN; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; CRESOL; SULFATE;

ADULT; AGE; ARTICLE; ATTENTION; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPTH PERCEPTION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; INFORMATION PROCESSING; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; PRIORITY JOURNAL; SEX DIFFERENCE; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; RENAL INSUFFICIENCY, CHRONIC;

AGED; CASE-CONTROL STUDIES; COGNITION DISORDERS; CRESOLS; EXECUTIVE FUNCTION; FEMALE; HUMANS; INDICAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RENAL INSUFFICIENCY, CHRONIC; SULFURIC ACID ESTERS;

EID: 84957571352     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2016.01.006     Document Type: Article

References (44)

1. Albert M.L. A simple test of visual neglect. Neurology 1973, 23(6):658-664.
2. Barreto F.C., Barreto D.V., Liabeuf S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 2009, 4(10):1551-1558.
3. Benton A.L., Hamsher K.D. Multilingual Aphasia Examination 1989, AJA Association, Iowa City.
4. Bugnicourt J.M., Godefroy O., Chillon J.M., Choukroun G., Massy Z.A. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J. Am. Soc. Nephrol. 2013, 24(3):353-363.
5. Buschke H., Fuld P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974, 24(11):1019-1025.
6. Butters M.A., Whyte E.M., Nebes R.D., et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch. Gen. Psychiatry 2004, 61(6):587-595.
7. Chen H.M., et al. Frontal function, disability and caregiver burden in elderly patients with major depressive disorder. Kaohsiung J. Med. Sci. 2010, 26(10):548-554.
8. 2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int. 2003, 63(5):1764-1775.
9. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000, 55(11):1621-1626.
10. Elias M.F., Elias P.K., Seliger S.L., Narsipur S.S., Dore G.A., Robbins M.A. Chronic kidney disease, creatinine and cognitive functioning. Nephrol. Dial. Transplant. 2009, 24(8):2446-2452.
11. Evenepoel P., Meijers B.K., Bammens B.R., Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. Suppl. 2009, 114:S12-19.
12. Gorelick P.B., Scuteri A., Black S.E., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42(9):2672-2713.
13. Helmer C., Stengel B., Metzger M., et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011, 77(23):2043-2051.
14. Iwata K., Watanabe H., Morisaki T., et al. Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure. Pharm. Res. 2007, 24(4):662-671.
15. Jourde-Chiche Dou L, Faure N., et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost.: JTH 2007, 5(6):1302-1308.
16. Kimmel P.L., Thamer M., Richard C.M. Psychiatric illness in patients with end-stage renal disease. Am. J. Med. 1998, 105(3):214-221.
17. Levey A.S., Coresh J., Greene T., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007, 53(4):766-772.
18. Madero M., Sarnak Gul A Cognitive function in chronic kidney disease. Semin. Dial. 2008, 21(1):29-37.
19. Meijers B.K., Claes K., Bammens B., et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5(7):1182-1189.
20. Meyer T.W., Leeper E.C., Bartlett D.W., et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J. Am. Soc. Nephrol. 2004, 15(7):1927-1935.
21. Motojima M., Hosokawa A., Yamato H., Muraki T., Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003, 63(5):1671-1680.
22. Murray A.M., Knopman D.S. Cognitive impairment in CKD: no longer an occult burden. Am. J. Kidney Dis. 2010, 56(4):615-618.
23. Murray A.M. The brain and the kidney connection: a model of accelerated vascular cognitive impairment. Neurology 2009, 73(12):916-917.
24. Newman A.B., Fitzpatrick A.L., Lopez O., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc. 2005, 53(7):1101-1107.
25. O'Brien J.T., Erkinjuntti T., Reisberg B., et al. Vascular cognitive impairment. Lancet Neurol. 2003, 2(2):89-98.
26. Ohtsuki S., Asaba H., Takanaga H., et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J. Neurochem. 2002, 83(1):57-66.
27. Paciaroni M., Bogousslavsky J. Connecting cardiovascular disease and dementia: further evidence. J. Am. Heart Assoc. 2013, 2(6):e000656.
28. Radic J., Ljutic D., Radic M., Kovacic V., Sain M., Curkovic K.D. The possible impact of dialysis modality on cognitive function in chronic dialysis patients. Neth. J. Med. 2010, 68(4):153-157.
29. Reitan R. Manual for Administration of Neuropsychological Test Batteries for Adults and Children 1978, Reitan Neuropsychology Laboratories, Inc., Tucson, AZ.
30. Roman G.C., Royall D.R. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999, 3(13 Suppl):S69-80.
31. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am. J. Kidney Dis. 2006, 47(4):565-577.
32. Sehgal A.R., Grey S.F., DeOreo P.B., Whitehouse P.J. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am. J. Kidney Dis. 1997, 30(1):41-49.
33. Seliger S.L., Siscovick D.S., Stehman-Breen C.O., et al. Moderate renal impairment and risk of dementia among older adults: the cardiovascular health cognition study. J. Am Soc Nephrol 2004, 15(7):1904-1911.
34. Sirich T.L., Funk B.A., Plummer N.S., Hostetter T.H., Meyer T.W. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J. Am. Soc. Nephrol. 2014, 25(3):615-622.
35. Sudo F.K., Alves G.S., Ericeira-Valente L., et al. Executive testing predicts functional loss in subjects with white matter lesions. Neurocase 2014, 1-9.
36. Sunrise-Editors Operating Insturctions for Sunrise Systmes: Continuous Performance Task 1995, Sunrise Systems, Inc., Washington.
37. Tamura Kurella, Yaffe V., et al. Kidney function and cognitive impairment in US adults: the reasons for geographic and racial differences in stroke (REGARDS) study. Am. J. Kidney Dis. 2008, 52(2):227-234.
38. Tsai C.F., Wang S.J. Moderate chronic kidney disease is associated with reduced cognitive performance in midlife women. Kidney Int. 2010, 78(6):605-610.
39. Tsang Yeh YC, et al. Subtypes of mild cognitive impairment among the elderly with major depressive disorder in remission. Am. J. Geriatr. Psychiatry 2011, 19(11):923-931.
40. Wang F., Zhang L., Wang Liu L Level of kidney function correlates with cognitive decline. Am. J. Nephrol. 2010, 32(2):117-121.
41. Watanabe K., Watanabe T., Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology 2014, 44:184-193.
42. Wechsler D. Wechsler Memory Scale-Revised (WMS-R) Manual 1987, The Psychological Corporation, San Antonio, TX.
43. Yamamoto H., Tsuruoka S., Ioka T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006, 69(10):1780-1785.
44. Yang A.C., Tsai S.J., et al. Association between renal function and cognitive performance in elderly community-dwelling men without dementia. J. Am. Geriatr Soc. 2010, 58(10):2046-2048.